Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRSN Mersana Therapeutics Inc.

Trading 04-02 11:56:23 EDT

0.3667

+0.0324

+9.69%

High0.3689	Low0.3200	Vol620.86K
Open0.3229	D1 Closing0.3343	Amplitude14.63%
Mkt Cap45.70M	Tradable Cap29.31M	Total Shares124.63M
T/O217.46K	T/O Rate0.78%	Tradable Shares79.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MRSN","market":"US","secType":"STK","nameCN":"Mersana Therapeutics Inc.","latestPrice":0.3667,"timestamp":1743609368782,"preClose":0.3343,"halted":0,"volume":620864,"delay":0,"floatShares":79932197,"shares":124631339,"eps":-0.56465,"marketStatus":"Trading","change":0.0324,"latestTime":"04-02 11:56:23 EDT","open":0.3229,"high":0.3689,"low":0.32,"amount":217461.19217664,"amplitude":0.146276,"askPrice":0.3689,"askSize":600,"bidPrice":0.366,"bidSize":909,"shortable":3,"etf":0,"ttmEps":-0.56465,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743624000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1498622400000,"exchange":"NASDAQ","adjPreClose":0.3343,"preHourTrading":{"tag":"盘前","latestPrice":0.3306,"preClose":0.3343,"latestTime":"09:12 EDT","volume":450,"amount":150.0602085,"timestamp":1743599527410},"postHourTrading":{"tag":"盘后","latestPrice":0.339,"preClose":0.3343,"latestTime":"19:42 EDT","volume":4181,"amount":1441.7367,"timestamp":1743550945936},"volumeRatio":0.366566,"impliedVol":0.2113,"impliedVolPercentile":0.0558},"requestUrl":"/m/hq/s/MRSN","defaultTab":"news","newsList":[{"id":"2524118305","title":"Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2524118305","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524118305?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:01","pubTimestamp":1743508860,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April  01, 2025  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053318/0/en/Mersana-Therapeutics-Announces-Upcoming-Oral-Presentation-of-Emi-Le-Clinical-Data-at-European-Society-for-Medical-Oncology-ESMO-Breast-Cancer-2025-Annual-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","LENZ","BK4563","BK4139"],"gpt_icon":0},{"id":"2517156283","title":"Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156283","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156283?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 19:19","pubTimestamp":1741259953,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics, Inc.  investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$40m beat estimates by a substantial 30% margin. Unfortunately, Mersana Therapeutics also reported a statutory loss of US$0.56 per share, which at least was smaller than the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest  post-earnings forecasts for next year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-mersana-therapeutics-inc-nasdaq-111913239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRSN",".IXIC","NDAQ"],"gpt_icon":1},{"id":"2517918486","title":"Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2517918486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517918486?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 19:10","pubTimestamp":1741173031,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics, Inc.  shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.Following the latest upgrade, the current consensus, from the ten analysts covering Mersana Therapeutics, is for revenues of US$25m in 2025, which would reflect a disturbing 37% reduction in Mersana Therapeutics' sales over the past 12 months. Per-share losses are expected to explode, reaching US$0.71 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$23m and losses of US$0.71 per share in 2025. So there's definitely been a change in sentiment in this update, with the analysts upgrading this year's revenue estimates, while at the same time holding losses per share steady.Check out our latest analysis for Mersana Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/industry-analysts-just-made-captivating-111031443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","MRSN","NDAQ"],"gpt_icon":0},{"id":"2516675349","title":"Truist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675349?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:38","pubTimestamp":1741091915,"startTime":"0","endTime":"0","summary":"In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-mersana-therapeutics-mrsn-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-mersana-therapeutics-mrsn-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRSN"],"gpt_icon":0},{"id":"2516199627","title":"Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2516199627","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516199627?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:07","pubTimestamp":1741086460,"startTime":"0","endTime":"0","summary":"NasdaqGS:MRSN Earnings and Revenue Growth March 4th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 30%. Earnings per share  also surpassed analyst estimates by 8.2%.Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are down 14% from a week ago.Be aware that  Mersana Therapeutics is showing  4 warning signs in our investment analysis and 2 of those shouldn't be ignored...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mersana-therapeutics-full-2024-earnings-110740954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","MRSN"],"gpt_icon":0},{"id":"2516437416","title":"Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2516437416","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516437416?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 15:00","pubTimestamp":1741071640,"startTime":"0","endTime":"0","summary":"Cash, Cash Equivalents, and Marketable Securities: $134.6 million at the end of 2024.Net Cash Used in Operating Activities: $19.3 million for Q4 2024, down from $32 million in Q4 2023.Collaboration Revenue: $16.4 million for Q4 2024, up from $10.7 million in Q4 2023.Research & Development Expenses: $22.3 million for Q4 2024, compared to $21.5 million in Q4 2023.General & Administrative Expenses: $8.9 million for Q4 2024, down from $10.1 million in Q4 2023.Net Loss: $14.1 million for Q4 2024, compared to $19.5 million in Q4 2023.GuruFocus has detected 8 Warning Signs with MRSN.Mersana Therapeutics Inc  reported positive initial clinical data for its lead dolasynthen ADC, Emi-Le, and started the expansion portion of its Phase 1 trial.Emi-Le was granted an additional fast track designation for a growing portion of the breast cancer population.Mersana's financial position is strong, with $134.6 million in cash, cash equivalents, and marketable securities, expected to support operations int","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mersana-therapeutics-inc-mrsn-q4-070040881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRSN"],"gpt_icon":0},{"id":"2516617757","title":"Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2516617757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516617757?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 14:01","pubTimestamp":1741068112,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics (MRSN) has disclosed a new risk, in the Accounting & Financial Operations category. Mersana Therapeutics faces significant bus...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mersana-therapeutics-viability-in-question-amidst-persistent-financial-losses-and-funding-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mersana-therapeutics-viability-in-question-amidst-persistent-financial-losses-and-funding-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4563","MRSN","LENZ"],"gpt_icon":0},{"id":"2516461619","title":"Q4 2024 Mersana Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2516461619","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516461619?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 12:09","pubTimestamp":1741061365,"startTime":"0","endTime":"0","summary":"Jason Fredette; Senior Vice President, Investor Relations & Corporate Communications; Mersana Therapeutics Inc. Martin Huber; President, Chief Executive Officer, Director; Mersana Therapeutics Inc. Brian Deschuytner; Chief Financial Officer, Chief Operating Officer, Senior Vice President; Mersana Therapeutics Inc. Good morning, and welcome to Mersana Therapeutics fourth quarter and year end 2024 conference call. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to turn the conference over to Jason Fredette, Senior Vice President, Investor Relations & Corporate Communications. Please proceed.Thank you, Jason, and good morning, everyone. Over the past several months, we have accomplished a great deal here at Mersana. Most notably, with our lead dolasynthen ADC, Emi-Le, we reported positive initial clinical data, started the expansion portion of our Phase 1 trial and were granted an additional fast ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-mersana-therapeutics-inc-040925966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRSN","PFE","LENZ"],"gpt_icon":1},{"id":"2516658420","title":"Mersana Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658420","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516658420?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 00:00","pubTimestamp":1741017604,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryMersana Therapeutics Inc MRSN.OQ reported a quarterly adjusted loss of 11 cents per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL5N3PM1J9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN"],"gpt_icon":0},{"id":"2516631155","title":"Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631155","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631155?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 21:10","pubTimestamp":1741007404,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics, Inc.  came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 31.25%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.09, delivering a surprise of 50%.Mersana Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $16.36 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 154.92%. This compares to year-ago revenues of $10.7 million. The company has topped consensus revenue estimates two times over the last four quarters.While Mersana Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?Investors should be mindful of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mersana-therapeutics-inc-mrsn-reports-131004291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRSN"],"gpt_icon":0},{"id":"2516687240","title":"Mersana Therapeutics Q4 EPS $(0.11) Beats $(0.15) Estimate, Sales $16.36M Beat $7.71M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687240","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687240?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:03","pubTimestamp":1741003399,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 31.25 percent increase over losses of $(0.16) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44073412/mersana-therapeutics-q4-eps-0-11-beats-0-15-estimate-sales-16-36m-beat-7-71m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","MRSN"],"gpt_icon":0},{"id":"2516871436","title":"BRIEF-Mersana Therapeutics Q4 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2516871436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516871436?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:02","pubTimestamp":1741003328,"startTime":"0","endTime":"0","summary":"BRIEF-Mersana Therapeutics Q4 EPS USD -0.11\n\n\nMar 03 (Reuters) - Mersana Therapeutics Q4 net income USD -14.117 million.\n\nQ4 collaboration revenue USD 16.361 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nPLXDEBF30:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN"],"gpt_icon":0},{"id":"2516268716","title":"Mersana Therapeutics Q4 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2516268716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516268716?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:01","pubTimestamp":1741003283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nPLXDEBF30:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MRSN","BK4563"],"gpt_icon":0},{"id":"2516687262","title":"Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687262","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687262?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:01","pubTimestamp":1741003260,"startTime":"0","endTime":"0","summary":"Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-Le. Initiated first expansion cohort in patients with triple-negative breast cancer  previously treated with at least one topoisomerase-1 inhibitor  ADC. Emiltatug Ledadotin In January 2025, Mersana announced positive initial Phase 1 clinical data for Emi-Le, the company’s lead Dolasynthen ADC candidate targeting B7-H4, from 130 patients who were enrolled in dose escalation and backfill cohorts as of a December 13, 2024 data cutoff. The company also announced that Emi-Le had received a second Fast Track designation from the U.S. Food and Drug Administration .In 2025, Mersana plans to initiate expansion enrollment at a second dose in patients with TNBC who have received one to four prior lines of treatment, including at least one prior topo-1 ADC. The company also plans to present additional Phase 1 clinical data from dose escalation and backfill cohorts in 2025.XMT-2056Mersana has continue","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mersana-therapeutics-provides-business-announces-120100840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRSN","BK4563","BK4139","LENZ"],"gpt_icon":0},{"id":"2516687855","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687855","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687855?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 19:00","pubTimestamp":1740999600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·AG Mtge Invst Trst                              4Q       .20   6:30 AM. ·BRC Inc Class A                                 4Q      (.01)      AMC. ·Burford Capital Ltd                              4Q       .54   7:00 AM. ·Crawford & Co                                  4Q       .23   4:15 PM. ·Dave Inc. Class A                               4Q       .42       AMC. ·Heidrick & Struggles                            4Q       .63   4:01 PM. ·Hut 8 Corp.                                      4Q       .04   6:30 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKTA","HUT","PLUG","OOMA","FATE","EVGO","SNDX","CRC","DAVE","NOMD","YMAB","ESPR","INO","NPCE","CLRB","EBS","RPTX","PMTS","TKNO","CMRX","OCUL","SQM","BWEN","BUR","RIGL","FLUT","JRVR","ANF","STIM","MITT","CTOS","GTLB","CRDO","AZO","BLFS","FTRE","SPHR","CRCT","NVRO","RPAY","SCM","DSP","EC","EOSE","NESR","SOPH","WVE","BMEA","BRCC","MRSN"],"gpt_icon":0},{"id":"2516010933","title":"BRIEF-Mersana Therapeutics Receives Nasdaq Non-Compliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2516010933","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516010933?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 05:21","pubTimestamp":1740777679,"startTime":"0","endTime":"0","summary":"BRIEF-Mersana Therapeutics Receives Nasdaq Non-Compliance NoticeFeb 28 (Reuters) - Mersana Therapeutics Inc MRSN.O:MERSANA THERAPEUTICS INC - RECEIVES NASDAQ NON-COMPLIANCE NOTICESource text: [ID:n0001104659-25-019146]Further company coverage: MRSN.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ1TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","BK4139","BK4563"],"gpt_icon":0},{"id":"2514241553","title":"Mersana Therapeutics Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514241553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514241553?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 21:43","pubTimestamp":1740750188,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics Inc  expected to post a loss of16cents a share - Earnings Preview Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected to show a fall in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL5N3PJ1D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN"],"gpt_icon":0},{"id":"2514070520","title":"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514070520","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514070520?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 05:01","pubTimestamp":1740430860,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb.  24, 2025  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/24/3031499/0/en/Mersana-Therapeutics-to-Host-Fourth-Quarter-and-Year-End-2024-Conference-Call-on-March-3-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4588","MRSN","BK4563","LENZ","HST","BK4585","BK4139","BK4181"],"gpt_icon":0},{"id":"2513213587","title":"Mersana Therapeutics Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2513213587","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513213587?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:46","pubTimestamp":1740404766,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics Inc  expected to post a loss of16cents a share - Earnings Preview Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected to show a fall in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL5N3PF1A7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN"],"gpt_icon":0},{"id":"2509779029","title":"Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509779029","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509779029?lang=en_us&edition=full_marsco","pubTime":"2025-02-08 05:05","pubTimestamp":1738962300,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb.  07, 2025  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/07/3023013/0/en/Mersana-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LU2210150020.SGD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","BK4585","BK4112",".IXIC","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","MRSN","IE00BGHQF748.EUR","BK4139","BK4563","IE00B3QW5Z07.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mersana.com","stockEarnings":[{"period":"1week","weight":-0.254},{"period":"1month","weight":-0.3613},{"period":"3month","weight":-0.7662},{"period":"6month","weight":-0.8345},{"period":"1year","weight":-0.9244},{"period":"ytd","weight":-0.7662}],"compareEarnings":[{"period":"1week","weight":-0.0252},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0121},{"period":"1year","weight":0.0743},{"period":"ytd","weight":-0.0428}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.054779},{"month":2,"riseRate":0.5,"avgChangeRate":0.134625},{"month":3,"riseRate":0,"avgChangeRate":-0.187861},{"month":4,"riseRate":0.375,"avgChangeRate":0.020595},{"month":5,"riseRate":0.428571,"avgChangeRate":0.275375},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.078008},{"month":7,"riseRate":0.25,"avgChangeRate":-0.160523},{"month":8,"riseRate":0.5,"avgChangeRate":0.058223},{"month":9,"riseRate":0.25,"avgChangeRate":-0.095374},{"month":10,"riseRate":0.25,"avgChangeRate":-0.038972},{"month":11,"riseRate":0.625,"avgChangeRate":0.219913},{"month":12,"riseRate":0.375,"avgChangeRate":0.000399}],"exchange":"NASDAQ","name":"Mersana Therapeutics Inc.","nameEN":"Mersana Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mersana Therapeutics Inc.(MRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mersana Therapeutics Inc.,MRSN,Mersana Therapeutics Inc.股票,Mersana Therapeutics Inc.股票老虎,Mersana Therapeutics Inc.股票老虎国际,Mersana Therapeutics Inc.行情,Mersana Therapeutics Inc.股票行情,Mersana Therapeutics Inc.股价,Mersana Therapeutics Inc.股市,Mersana Therapeutics Inc.股票价格,Mersana Therapeutics Inc.股票交易,Mersana Therapeutics Inc.股票购买,Mersana Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mersana Therapeutics Inc.(MRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction